Essential Premium

Even as Healthcare Gets Pulled Down With AI and Tech, Janus Is Bullish

Recent volatility “could help refocus investor attention on fundamentals and the attractive entry points in these high-quality biotech companies.”

Corporate Funds & Insurance Portfolios Roundtable

March 9-10, 2027

Podcast: Are Hedge Funds Worth It?

On “In Conversation with Julie Segal,” Paul Zummo and Jon Caplis discuss the damage caused by incomplete data, how everyone wants to be a multi-strat, and why hedge funds are not an asset class. 

Sponsored

Fireside Chat- Private Credit's Next Chapter: Differentiation, Discipline, and Opportunity

Hedge Funds Embrace Robotics

At least 75 such companies are unicorns, 45 of which attained this status this year.

Related Content

Janus Henderson Maintains Its Wide Lead in Biotech

Steve Taub

Affinity, Janus Henderson Outpace Biopharma Peers in Tough Month

Stephen Taub

One of the Best Market Neutral Funds Is Run by a Robot

Julie Segal

Endowments & Foundations Roundtable West

February 8-10, 2027 | Fairmont Scottsdale Princess

1270 Avenue of the Americas, Suite 1120

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram